AxoGen

Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. The firm’s products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AxoGen reports robust Q4 earnings, eyes growth through innovation

AxoGen's Q4 2022 performance showcased revenue growth, strong margins, and a focus on market expansion through core accounts.
The company's strengths lie in innovative products, high surgeon adoption rates, and a clear roadmap for future growth.
Challenges include post-COVID segment recovery, referral process acceleration, and balancing expenses with revenue.
Opportunities in rep productivity enhancement, product innovation, and regulatory milestones position AxoGen for continued success and market leadership.

AxoGen reports robust Q1 revenue growth and innovation focus

AxoGen's Q1 performance reflects strong revenue growth and market penetration strategies, supported by innovative product introductions and a clear outlook for future revenue and margin improvements.
While facing challenges in managing expenses and executing facility transitions, AxoGen's focus on niche market segments and commitment to R&D present opportunities for sustained growth and profitability.
Overall, AxoGen's strategic direction, emphasis on product innovation, and dedication to improving patient outcomes position the company well for long-term success and market expansion.

AxoGen reports revenue growth and product expansion in Q2

AxoGen's Q2 performance showed revenue growth, increased active accounts, and new product introductions.
Strengths include focus on Core Accounts, sales efforts, and no supply challenges affecting production.
Challenges include validation delay impacting gross margin and extended BLA submission timeline.
Opportunities lie in upcoming product launches, growth in scheduled procedures, and commitment to patient outcomes.

AxoGen reports robust Q3 growth driven by innovative nerve solutions

AxoGen's Q3 performance reflects strong revenue growth driven by emergent trauma and scheduled procedures, supported by a focus on core accounts and innovative products.
While challenges like a net loss persist, opportunities lie in market expansion, regulatory approvals, and maintaining revenue guidance, positioning the company for future success.
Investors should monitor AxoGen's ability to manage expenses, achieve profitability, and leverage its product innovations to drive sustainable growth and shareholder value.

AxoGen reports robust revenue growth, addresses supply chain challenges

AxoGen's strong revenue growth and product innovation demonstrate resilience and market potential.
While challenges like supply chain disruptions persist, the company's focus on cost management and customer relationships is key.
Opportunities lie in market expansion through new products and sustained revenue growth in the coming year.
Analysts are optimistic about AxoGen's performance and strategic direction, emphasizing the need for operational efficiency.

AxoGen reports revenue growth and innovation drive amidst challenges

AxoGen's Q1 2024 performance reflects revenue growth and strategic focus on core accounts and innovation. While challenges like net losses persist, opportunities lie in upcoming product approvals and enhanced transparency. The company's maintained full-year guidance indicates a positive outlook for revenue and cash flow.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Dr. Tyndall is currently the Executive Vice President for Health Affairs and Dean of Morehouse School of Medicine. Dr. Tyndall is currently the Executive Vice President for Health Affairs and Dean of Morehouse School of Medicine.

Axogen, Inc. announces the appointment of Adrian Tyndall, M.D. MPH, FACEP to its Board of Directors and the retirement of founding Director Mark Gold, M.D.

AxoGen (AXGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

AxoGen (AXGN) Upgraded to Buy: Here's What You Should Know

ALACHUA and TAMPA, Fla., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report third quarter 2022 financial results on Tuesday, November 8, 2022 before the market opens. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release.

Axogen, Inc. to report third quarter 2022 financial results and host conference call on November 8, 2022

AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

AxoGen (AXGN) Soars 8.6%: Is Further Upside Left in the Stock?

Industry leading nerve repair surgeons will discuss data-driven best practices during symposium session Industry leading nerve repair surgeons will discuss data-driven best practices during symposium session

Axogen to Participate in the 77th Annual Meeting of the American Society for Surgery of the Hand

The consensus price target hints at an 89.4% upside potential for AxoGen (AXGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think AxoGen (AXGN) Could Surge 89%: Read This Before Placing a Bet

AxoGen, Inc. (NASDAQ:AXGN ) Q2 2022 Results Conference Call August 3, 2022 4:30 PM ET Company Participants Ed Joyce - Director, IR Karen Zaderej - Chairman, President & CEO Peter Mariani - EVP & CFO Conference Call Participants Operator Welcome to the AxoGen Second Quarter 2022 Conference Call. At this time, all participants are in a listen-only mode.

AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q2 2022 Results - Earnings Call Transcript

AxoGen (AXGN) delivered earnings and revenue surprises of 60% and 5.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

AxoGen (AXGN) Reports Q2 Loss, Tops Revenue Estimates

ALACHUA, Fla. and TAMPA, Fla., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the second quarter ended June 30, 2022.

Axogen, Inc Reports 2022 Second Quarter Financial Results

AxoGen is set to report Q2 FY22 earnings on Wednesday, following a period of flat performance on the chart. The company released top-line forecasts in its earnings pre-release from July, implying a period of growth.

AxoGen: Investors Are Positioned Long Leading Into Q2 FY22 Earnings

ALACHUA. Fla. and TAMPA, Fla, July 29, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, chairman, CEO, and president, will present at Canaccord Genuity's 42nd Annual Growth Conference in Boston. The presentation is scheduled for Wednesday, August 10, 2022, at 12:30 p.m. ET.

Axogen, Inc. to present at Canaccord Genuity's 42nd Annual Growth Conference

Organizational updates are part of plan to bring additional focus on leveraging clinical data to accelerate market development and the pace of innovation

Axogen, Inc. Announces Organizational Updates, Preliminary Second Quarter Revenue and Reaffirms Full-Year 2022 Financial Guidance

Burke brings 25+ years of global financial leadership experience to the Axogen, Inc. Board of Directors Burke brings 25+ years of global financial leadership experience to the Axogen, Inc. Board of Directors

Axogen, Inc. Appoints William Burke to Board of Directors

AxoGen, Inc. (NASDAQ:AXGN ) Q1 2022 Results Conference Call May 4, 2022 4:30 PM ET Company Participants Ed Joyce - Director, IR Karen Zaderej - Chairman, President & CEO Peter Mariani - EVP & CFO Erick DeVinney - VP of Peripheral Nerve Science & Clinical Innovation Conference Call Participants Erin Fahey - SVB Leerink Frank Pinal - Jefferies Ross Osborn - Cantor Fitzgerald Dave Turkaly - JMP Securities Operator Good day, ladies and gentlemen, and welcome to the AxoGen, Inc. Reports First Quarter Earnings Call. [Operator Instructions] At this time, it is my pleasure to turn the floor over to your host, Ed Joyce.

AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q1 2022 Results - Earnings Call Transcript

Axogen Inc (NASDAQ: AXGN) announced topline results from its RECON Clinical Study comparing Avance Nerve Graft to conduits in digital nerve injuries.  Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral.

Axogen Aces Phase 3 Study For Avance Nerve Graft

ALACHUA, Fla. and TAMPA, Fla., May 04, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2022.

Axogen, Inc Reports 2022 First Quarter Financial Results

RECON achieved its Primary Endpoint, a critical milestone toward transitioning Avance Nerve Graft to a licensed biologic and further supporting the expanded adoption of Avance RECON achieved its Primary Endpoint, a critical milestone toward transitioning Avance Nerve Graft to a licensed biologic and further supporting the expanded adoption of Avance

Axogen, Inc. Announces Positive Topline Results from Phase 3 RECON(SM) Study for Avance® Nerve Graft

ALACHUA, Fla. and TAMPA, Fla., April 13, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2022 financial results on Wednesday, May 4, 2022 after the market closes. Axogen management will host an investment-community conference call and webcast following the release at 4:30 p.m. ET.

Axogen, Inc. to Report First Quarter 2022 Financial Results and Host Conference Call on May 4, 2022

ALACHUA, Fla. and TAMPA, Fla., March 17, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today published its inaugural Environmental, Social, and Governance (ESG) report highlighting the company's corporate responsibility and sustainability initiatives.

Axogen, Inc. publishes inaugural ESG Report

Axogen reported disappointing fourth quarter results, with procedure volume down 8% on issues related to COVID-19 and hospital staffing.

Axogen Needs RECON More Than Ever To Recharge The Bull Case

AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q4 2021 Results - Earnings Call Transcript

AxoGen (AXGN) delivered earnings and revenue surprises of 38.46% and 0.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

AxoGen (AXGN) Reports Q4 Loss, Tops Revenue Estimates

ALACHUA, Fla. and TAMPA, Fla., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2021.

Axogen, Inc. Reports 2021 Fourth Quarter and Full-Year Financial Results

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: AxoGen (AXGN) Q4 Earnings Expected to Decline

ALACHUA, Fla. and TAMPA, Fla., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report fourth quarter and full-year 2021 financial results on Tuesday, February 22, 2022 after the market closes. Axogen management will host an investment-community conference call and webcast following the release at 4:30 p.m. ET.

News for AxoGen Stock (AXGN)